TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30429357

Group type: EXPERIMENTAL
Intervention: Oral administration of semaglutide coformulated with sodium N‐[8‐(2‐hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SNAC as an absorption enhancer.
Number of subjects: 0
Study: 28186441

Group type: EXPERIMENTAL
Intervention: High HGI
Number of subjects: 7226

Group type: EXPERIMENTAL
Intervention: Low HGI
Number of subjects: 7226

Group type: EXPERIMENTAL
Intervention: Every percentage increase in HGI
Number of subjects: 7226
Study: 25985734

Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir plus Ribavirin for 12 weeks
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir plus Ribavirin
Number of subjects: 337
Study: 24286335

Group type: COMPARATOR
Intervention: GSK315234 3 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSK315234 0.3 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSK315234 6 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSK315234 500 mg subcutaneous
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study: 21143498

Group type: EXPERIMENTAL
Intervention: Focussed prescribing teaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional teaching (Control)
Number of subjects: 0
Study: 18322078

Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 16988537

Group type: EXPERIMENTAL
Intervention: Xanax XR 1 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Xanax XR 3 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Xanax XR 1 mg and 3 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Xanax XR
Number of subjects: 24
Study: 12703834

Group type: EXPERIMENTAL
Intervention: fenta-7.5 (7.5 microg fentanyl)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: fenta-10 (10 microg fentanyl)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: fenta-12.5 (12.5 microg fentanyl)
Number of subjects: 45
Study: 11109505

Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of acenocoumarol
Number of subjects: 37

Group type: COMPARATOR
Intervention: Gradual withdrawal of acenocoumarol
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups (abrupt and gradual)
Number of subjects: 37
Study: 9122904

Group type: EXPERIMENTAL
Intervention: G-CSF at doses of 2, 5, 7.5, or 10 micrograms per kg per day for 5 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: G-CSF at doses of 7.5 or 10 micrograms per kg per day for both courses
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: G-CSF administration
Number of subjects: 19
Study: 8372870

Group type: EXPERIMENTAL
Intervention: Active induction of labor within 5 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 200
Study: 3784295

Group type: EXPERIMENTAL
Intervention: Free dopamine (DA) concentration in CRFh
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free norepinephrine (NE) concentration in CRFh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free epinephrine (EPI) concentration in CRFh
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfo-conjugated catecholamines in CRFh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucuro-conjugated dopamine (DA) concentration in CRFh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucuro-conjugated norepinephrine (NE) concentration in CRFh
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucuro-conjugated epinephrine (EPI) concentration in CRFh
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tyrosine, free and sulfo-conjugated catecholamines during hemodialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucuro-conjugated catecholamines during hemodialysis
Number of subjects: 0
Study: 30929067

Group type: EXPERIMENTAL
Intervention: Iodine-fortified toddler milk (21.1 µg iodine/100 g prepared drink)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Non-Fortified Milk (non-fortified cow's milk)
Number of subjects: 135
Study: 30096106

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 40 U
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 64 U
Number of subjects: 787

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (both dosages)
Number of subjects: 787
Study: 27659741

Group type: EXPERIMENTAL
Intervention: Integrated, home‐based, medical/nursing intervention plus a rehabilitation program (telesurveillance and home-based rehabilitation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study: 23913700

Group type: EXPERIMENTAL
Intervention: Mitomycin C group (13 patients)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (12 patients)
Number of subjects: 25
Study: 23265404

Group type: EXPERIMENTAL
Intervention: Acceptance-based coping strategies
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard cognitive reappraisal/distraction intervention
Number of subjects: 48
Study: 21453220

Group type: EXPERIMENTAL
Intervention: Ozone treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoride desensitizer (ALLSolutions, Dentsply)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxalate desensitizer (D/Sense Crystal, Centrix)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined use of ozone/fluoride
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined use of ozone/oxalate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water (Control)
Number of subjects: 60
Study: 18438853

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control group (OASIS study, untreated with anti-TNFalpha agents)
Number of subjects: 257
Study: 16290232

Group type: EXPERIMENTAL
Intervention: Maternal allergies
Number of subjects: 185
Study: 14675857

Group type: EXPERIMENTAL
Intervention: Educational intervention using the measure of educational material acceptability (EMA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational intervention using the knowledge acquisition questionnaire (KAQ)
Number of subjects: 0
Study: 11045316

Group type: EXPERIMENTAL
Intervention: Intraperitoneal calcitriol (i.p. calcitriol)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Oral calcitriol (p.o. calcitriol)
Number of subjects: 76
Study: 9363869

Group type: EXPERIMENTAL
Intervention: Warfarin with chemotherapy and radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no warfarin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 0
Study: 1607916

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDR) 12 mg/m2 daily for the first 3 days, followed by consolidation with IDR 15 mg/m2 on the first day of each cycle.
Number of subjects: 218

Group type: COMPARATOR
Intervention: Daunorubicin (DNR) 45 mg/m2 daily for the first 3 days, followed by consolidation with DNR 50 mg/m2 on the first day of each cycle.
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Late intensification (same drugs as induction, CA for 5 days and anthracycline for 2 days).
Number of subjects: 218
Study: 3769194

Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapy (group B)
Number of subjects: 20
Study: 29558927

Group type: EXPERIMENTAL
Intervention: Housing First
Number of subjects: 2039
Study: 26384097

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) as the only grafting material
Number of subjects: 27
Study: 24837860

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 222
Study: 23270519

Group type: EXPERIMENTAL
Intervention: 1200 mg extended-release guaifenesin, every 12 hours for 7 days
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study: 20643005

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg rocuronium (group R)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg atracurium (group A)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Both rocuronium and atracurium
Number of subjects: 232
Study: 18319587

Group type: EXPERIMENTAL
Intervention: Meal-replacement diet group (MRD-G; n = 60)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low-calorie diet group (LCD-G; n = 30)
Number of subjects: 90
Study: 19496195

Group type: EXPERIMENTAL
Intervention: Percutaneous ablation of feeding artery (PAA) before routine RFA treatment
Number of subjects: 154

Group type: COMPARATOR
Intervention: Routine RFA treatment
Number of subjects: 154
Study: 16151471

Group type: EXPERIMENTAL
Intervention: Darbepoetin 1 microg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Darbepoetin 4 microg/kg
Number of subjects: 12
Study: 11401006

Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (0 mg/day)
Number of subjects: 10
Study: 9569080

Group type: EXPERIMENTAL
Intervention: Neoral (5 mg/kg/day, administered q.12.h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Prednisolone (2 mg/kg/day) plus cyclophosphamide (2 mg/kg/day)
Number of subjects: 40
Study: 8045142

Group type: EXPERIMENTAL
Intervention: Amrinone 0.5 mg/kg followed by 5 micrograms/kg/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amrinone 0.5 mg/kg followed by 10 micrograms/kg/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amrinone 1.0 mg/kg followed by 10 micrograms/kg/min
Number of subjects: 10
Study: 3214958

Group type: EXPERIMENTAL
Intervention: Combined short-contact coal tar and dithranol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard short-contact dithranol therapy
Number of subjects: 19
Study: 31756059

Group type: COMPARATOR
Intervention: Standard-dose bevacizumab (10 mg/kg 2-weekly)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Reduced-dose bevacizumab (5 mg/kg 2-weekly)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: MGMT methylated tumors
Number of subjects: 118
Study: 30681617

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 30318264

Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detecting intracranial haemorrhage
Number of subjects: 21386

Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detecting types of intracranial haemorrhage
Number of subjects: 21386

Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detecting calvarial fractures
Number of subjects: 21386

Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detecting midline shift
Number of subjects: 21386

Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detecting mass effect
Number of subjects: 21386
Study: 26704617

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 769

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 769
Study: 24986944

Group type: EXPERIMENTAL
Intervention: Kinematically aligned TKR using patient-specific guides
Number of subjects: 88

Group type: COMPARATOR
Intervention: Mechanically aligned TKR using conventional instruments
Number of subjects: 88
Study: 22309046

Group type: EXPERIMENTAL
Intervention: Clopidogrel (0.20 mg/kg/day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: 5 µM ADP
Number of subjects: 49

Group type: COMPARATOR
Intervention: 5 µM TRAP
Number of subjects: 49
Study: 19087105

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 215

Group type: COMPARATOR
Intervention: Lifestyle management (LM)
Number of subjects: 215
Study: 17613606

Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - aerobic and strength exercise, 3 times a week for 5 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CG) - no change in exercise habits
Number of subjects: 16
Study: 16205095

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy; mean duration: 8.8 (1.7) years
Number of subjects: 72

Group type: COMPARATOR
Intervention: Untreated group (no GH therapy)
Number of subjects: 72
Study: 11821976

Group type: EXPERIMENTAL
Intervention: Insecticide spraying
Number of subjects: 6300

Group type: EXPERIMENTAL
Intervention: Pit latrines
Number of subjects: 6300

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6300
Study: 10422041

Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Conceiving women
Number of subjects: 69

Group type: COMPARATOR
Intervention: Nonconceiving women
Number of subjects: 69
Study: 8551492

Group type: EXPERIMENTAL
Intervention: Losartan potassium (50 mg titrated to 100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine ER (5 mg titrated to 10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Felodipine ER
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan potassium
Number of subjects: 0
Study: 2255259

Group type: EXPERIMENTAL
Intervention: Supported work program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional workshop services
Number of subjects: 0
Study: 396063

Group type: EXPERIMENTAL
Intervention: Saralasin (10 microgram min‐1 kg‐1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Saralasin (40 microgram min‐1 kg‐1)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Low salt intake (15 mmol of Na+/day)
Number of subjects: 3

Group type: COMPARATOR
Intervention: High salt intake (290 mmol of Na+/day)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Saralasin (both doses)
Number of subjects: 3
Study: 31486420

Group type: EXPERIMENTAL
Intervention: CO2-laser myringotomy on the 3rd day of hospital treatment
Number of subjects: 172

Group type: COMPARATOR
Intervention: CO2-laser myringotomy on the 7th day of hospital treatment
Number of subjects: 172
Study: 28129268

Group type: EXPERIMENTAL
Intervention: Allgöwer-Donati
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vertical mattress
Number of subjects: 30
Study: 26418813

Group type: EXPERIMENTAL
Intervention: Home-based counselling strategy
Number of subjects: 24381
Study: 23823612

Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope (GVL)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Direct laryngoscope (DL)
Number of subjects: 623
Study: 21967819

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800

Group type: COMPARATOR
Intervention: PES
Number of subjects: 1800
Study: 19480558

Group type: EXPERIMENTAL
Intervention: Intranasal dosing of PF-219061
Number of subjects: 0
Study: 17461981

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg (SIMVA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of simvastatin 40 mg and ezetimibe 10 mg (EZE/SIMVA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No lipid-lowering drugs (NLLD)
Number of subjects: 60
Study: 15465744

Group type: EXPERIMENTAL
Intervention: Formula-fed infants with whey:casein 60:40
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Formula-fed infants with whey:casein 40:60
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Formula-fed infants with whey:casein 20:80
Number of subjects: 18

Group type: COMPARATOR
Intervention: Infants fed mother's milk
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Formula-fed infants
Number of subjects: 18
Study: 12086558

Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 20

Group type: COMPARATOR
Intervention: Literature review of concentration‐effect relationships
Number of subjects: 20
Study: 9703185

Group type: EXPERIMENTAL
Intervention: Queckenstedt's manoeuvre (cranial venous dilatation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo procedure (equal pressure applied to the lateral aspect of the neck)
Number of subjects: 20
Study: 8010332

Group type: EXPERIMENTAL
Intervention: Beta-carotene (300 mg daily for 30 days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Wheat germ oil capsules (control group)
Number of subjects: 95
Study: 2690721

Group type: EXPERIMENTAL
Intervention: High compression stockings (40 mmHg) after varicose vein surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low compression stockings (15 mmHg) after varicose vein surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High compression stockings after sclerotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elastocrepe bandages with stockings after sclerotherapy
Number of subjects: 0
Study: 1143972

Group type: EXPERIMENTAL
Intervention: six visits by a physician
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: three visits by a physician
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: six visits by a pediatric nurse practitioner (PNP)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: three visits by a PNP
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: clinic setting
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: private-practice setting
Number of subjects: 246
Study: 30293449

Group type: EXPERIMENTAL
Intervention: MSN (extended-release morphine sulfate with sequestered naltrexone)
Number of subjects: 1899

Group type: EXPERIMENTAL
Intervention: Crushed MSN
Number of subjects: 1899
Study: 27847195

Group type: EXPERIMENTAL
Intervention: Augmented Cognitive Behavioral Therapy (CBT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 61
Study: 25607833

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) therapy
Number of subjects: 155

Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 155
Study: 24156687

Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy plus Kinesio Taping
Number of subjects: 148

Group type: COMPARATOR
Intervention: Guideline-Endorsed Conventional Physiotherapy
Number of subjects: 148
Study: 21057823

Group type: EXPERIMENTAL
Intervention: Plant sterol-enriched yoghurt
Number of subjects: 58
Study: 19133873

Group type: EXPERIMENTAL
Intervention: 15 mg/day elemental zinc syrup for 10 weeks
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo syrup without zinc for 10 weeks
Number of subjects: 218
Study: 17317583

Group type: EXPERIMENTAL
Intervention: ATG
Number of subjects: 54
Study: 15602192

Group type: EXPERIMENTAL
Intervention: HAART including LPV/r
Number of subjects: 120

Group type: COMPARATOR
Intervention: Second line HAART
Number of subjects: 120

Group type: COMPARATOR
Intervention: First line HAART
Number of subjects: 120
Study: 11574498

Group type: EXPERIMENTAL
Intervention: 0.5 mg gemeprost
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: 800 microg misoprostol
Number of subjects: 999

Group type: COMPARATOR
Intervention: Comparison of side effects
Number of subjects: 999
Study: 9822168

Group type: EXPERIMENTAL
Intervention: Radiotherapy alone (median dose 4470 cGy)
Number of subjects: 29
Study: 7664428

Group type: COMPARATOR
Intervention: Medical treatment (sedation and blood pressure control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Early surgical repair
Number of subjects: 25

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 25

Group type: COMPARATOR
Intervention: Medical and surgical therapy
Number of subjects: 25
Study: 2751284

Group type: EXPERIMENTAL
Intervention: 4 g azlocillin every 6 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 g azlocillin every 8 h
Number of subjects: 12
Study: 73744

Group type: EXPERIMENTAL
Intervention: 80 I.U. of corticotrophin (A.C.T.H.) in gelatin solvent
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no A.C.T.H. administration)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Patients with fractures to the upper shaft of the femur
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Total-hip replacement with A.C.T.H. administration
Number of subjects: 85
Study: 31849079

Group type: EXPERIMENTAL
Intervention: PVAM (Pulmonary Vein Antrum Modification)
Number of subjects: 180

Group type: COMPARATOR
Intervention: CPVI (Circumferential Pulmonary Vein Isolation)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PVAM-PVI subgroup
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PVAM-non-PVI subgroup
Number of subjects: 180

Group type: COMPARATOR
Intervention: CPVI group
Number of subjects: 180
Study: 30950165

Group type: EXPERIMENTAL
Intervention: Antenatal milk expression (AME) intervention involving demonstration and practice with a lactation consultant, reinforcement at weekly visits until delivery, and daily home practice.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Antenatal milk expression (AME) intervention
Number of subjects: 19
Study: 28394498

Group type: EXPERIMENTAL
Intervention: Degarelix (240/80 mg)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Goserelin (3.6 mg) plus Bicalutamide (50 mg)
Number of subjects: 463
Study: 26288165

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 23395281

Group type: EXPERIMENTAL
Intervention: Prednisone (1 mg/kg/d, orally)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Allopurinol (100 mg, thrice daily, orally)
Number of subjects: 34
Study: 20561880

Group type: EXPERIMENTAL
Intervention: Women with CHD and depressive symptoms
Number of subjects: 1951

Group type: COMPARATOR
Intervention: Men with CHD and depressive symptoms
Number of subjects: 1951
Study: 19011146

Group type: EXPERIMENTAL
Intervention: Disease-specific enteral formula (Diben)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard formula (control)
Number of subjects: 105
Study: 16739846

Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion plus western medicine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 82
Study: 15119917

Group type: EXPERIMENTAL
Intervention: IVIG (1 g/kg on 2 consecutive days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 30
Study: 15592696

Group type: EXPERIMENTAL
Intervention: External beam irradiation (EBI) combined with interstitial HDR brachytherapy boost (mean dose 18 Gy)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sole brachytherapy (mean dose 28 Gy)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: External beam irradiation (EBI) and brachytherapy boost
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sole brachytherapy
Number of subjects: 37